---
title: "Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Effects of other drugs"
description: "Formulary evidence on Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Effects of other drugs. Topics: Metabolizing enzymes in vitro: CYP2C8, CYP2C19, CYP3A4, and UGT isoforms; Strong CYP2C8 inducers and inhibitors: exclusion and washout before treatment; Strong CYP2C8 inducers and inhibitors: prohibited concomitant medications, with rifampin, gemfibrozil, and clopidogrel as examples; Protocol amendment driven by preliminary results of drug-drug interaction study 337HVPK21014; 1 further topic. 5 evidence topics quoted from 3 sources."
canonical: "https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/product-information-and-disease-description/effects-of-other-drugs"
published: "2026-11-18T22:34:49-05:00"
modified: "2026-11-18T22:34:49-05:00"
---

# Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Effects of other drugs

<a id="heading-2.1.2.9.1"></a>

## 2.1.2.9.1 Effects of Other Drugs on Lanifibranor

<a id="topic-2.1.2.9.1-1"></a>

### Metabolizing enzymes in vitro: CYP2C8, CYP2C19, CYP3A4, and UGT isoforms

> “Lanifibranor was observed in vitro to be metabolized either by enzymes of phase I (mainly via CYP isoforms CYP2C8, 2C19 and 3A4) and phase II (mainly via UGT 2B7, 1A1 and 1A3).”
> “No affinity of lanifibranor to uptake or efflux transporters as substrate was evidenced in vitro.”
> “No significant drug-drug interaction was observed with Simvastatin (<2-fold), and no PK/genotype (CYP450 isoenzymes and UGTs isoform) relationship has been identified.”

Source: [Inventiva NATIVE protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/70/NCT03008070/Prot_002.pdf)

<a id="topic-2.1.2.9.1-2"></a>

### Strong CYP2C8 inducers and inhibitors: exclusion and washout before treatment

> “Treatment with strong inducers or inhibitors of CYP2C8. When administered chronically, they should be replaced 3 months before Screening visit. If not administered chronically, they should be stopped at least 7 days before treatment initiation (See Section 6.7 and Section 13.2).”

Source: [Inventiva LEGEND protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/71/NCT05232071/Prot_000.pdf)

<a id="topic-2.1.2.9.1-3"></a>

### Strong CYP2C8 inducers and inhibitors: prohibited concomitant medications, with rifampin, gemfibrozil, and clopidogrel as examples

> “CYP2C8 strong inducers (e.g. rifampin). However, if medically necessary, these drugs may be taken for a maximum duration of 3 weeks.”
> “CYP2C8 strong inhibitors, when systemically administered, i.e. by oral, intra-venous or intra-muscular route of administration (e.g. gemfibrozil, clopidogrel).”
> “The antiplatelets agents (incl. low-dose aspirin, ticlopidine, prasugrel, ticagrelor) are allowed (but not clopidogrel).”

Source: [Inventiva LEGEND protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/71/NCT05232071/Prot_000.pdf)

<a id="topic-2.1.2.9.1-4"></a>

### Protocol amendment driven by preliminary results of drug-drug interaction study 337HVPK21014

> “Clarification regarding prohibited medication: treatment with substrates of CYP2B6 and CYP2C8, CYP2C8 strong inducers and CYP2C8 strong inhibitors excluded.”
> “Driven by the preliminary results of the Drug-Drug Interaction study 337HVPK21014”

Source: [Inventiva LEGEND protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/71/NCT05232071/Prot_000.pdf)

<a id="topic-2.1.2.9.1-5"></a>

### Concomitant PPAR agonists: fibrates and thiazolidinediones excluded

> “For obvious reasons, fibrates, as they are PPARα ligands, are not allowed, but dyslipidaemias can be treated with statins, which are allowed.”

Source: [Inventiva NATIVE protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/70/NCT03008070/Prot_002.pdf)

> “Treatment with PPAR-gamma agonists (thiazolidinediones [TZDs]) 12 months before screening or historical biopsy.”
> “Concomitant treatment with PPAR-alpha agonists (fibrates)”

Source: [ClinicalTrials.gov NCT04849728](https://clinicaltrials.gov/study/NCT04849728)

<a id="topic-2.1.2.9.1-6"></a>

### Published results of drug-drug interaction study 337HVPK21014

No evidence found.

## Related pages
- [Lanifibranor (IVA337): Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Terms and abbreviations](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/terms-and-abbreviations.md)
- [Lanifibranor (IVA337): Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/executive-summary.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Product information and disease description](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/product-information-and-disease-description.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Clinical evidence](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/clinical-evidence.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Economic information and modeling report](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/economics) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/economics.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: References](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/references) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/references.md)
